0
Es befinden sich keine Waren im Warenkorb !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Start > Galectin-9

Galectin-9

Brief Information

Name:Galactoside-binding lectin Galectin 9
Target Synonym:Ecalectin,Tumor antigen HOM-HD-21,Galectin-9,Lectin, Galactoside-Binding, Soluble, 9,LGALS9
Number of Launched Drugs:0
Number of Drugs in Clinical Trials:1
Lastest Research Phase:Phase 2 Clinical

Product ListCompare or Buy

Nach Produktstatus:
Nach Produktkategorie :
Nach Arten:
Nach Markierungen:
Kat. Nr. Arten Produktbeschreibung Struktur Reinheit Merkmal
LG9-H82H3 Human Biotinylated Human Galectin-9 / LGALS9 Protein, His,Avitag™ (SPR verified)
LG9-H82H3-structure
LG9-H82H3-sds
LG9-H5244 Human Human Galectin-9 / LGALS9 Protein, His Tag
LG9-H5244-structure
LG9-H5244-sds
ACRO Quality

Part of Bioactivity data

LG9-H82H3-SPR
 Galectin-9 SPR

Human TIM-3 (22-200) Protein, Fc Tag (Cat. No. TM3-H5258) immobilized on CM5 Chip can bind Biotinylated Human Galectin-9, His,Avitag (Cat. No. LG9-H82H3) with an affinity constant of 7.66 μM as determined in a SPR assay (Biacore 8K) (QC tested).

LG9-H5244-SPR
 Galectin-9 SPR

Human TIM-3 (22-200) Protein, Fc Tag (Cat. No. TM3-H5258) captured on CM5 chip via Anti-human IgG Fc antibodies surface can bind Human Galectin-9, His Tag (Cat. No. LG9-H5244) with an affinity constant of 57 nM as determined in a SPR assay (Biacore T200) (Routinely tested).

Synonym Name

Galectin-9,LGALS9,Ecalectin

Background

Galectin-9 (LGALS9) is also known as tumor antigen HOM-HD-21 and ecalectin. Galectins are a family of proteins defined by their binding specificity for β-galactoside sugars, such as N-acetyllactosamine (Galβ1-3GlcNAc or Galβ1-4GlcNAc), which can be bound to proteins by either N-linked or O-linked glycosylation. As for Galectin-9, it has high affinity for the Forssman pentasaccharide, and it is also the ligand for HAVCR2/TIM3. Forthermore, Galectin-9 stimulates bactericidal activity in infected macrophages by causing macrophage activation and IL1B secretion which restricts intracellular bacterial growth.

Clinical and Translational Updates

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
LYT-200 LYT-200 Phase 2 Clinical Puretech Health Solid tumours; Head and Neck Neoplasms; Myelodysplastic Syndromes; Carcinoma, Transitional Cell; Pancreatic Neoplasms; Cholangiocarcinoma; Colorectal Neoplasms; Leukemia, Myeloid, Acute; Neoplasm Metastasis Details

This web search service is supported by Google Inc.

totop
Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
Lichtstrasse 35,4056 Basel, Switzerland

Nachricht schicken